Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
18 mai 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of...
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
09 mai 2022 16h05 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
Atossa Therapeutics to Present at the Q2 Investor Summit Conference
27 avr. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
20 avr. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
23 mars 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...
Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen
08 mars 2022 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
28 févr. 2022 16h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
27 janv. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
18 janv. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
22 déc. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...